Zoledronic acid (Zometa) and persistent/dormant cells
 

Anticancer Res. 2010 May;30(5):1807-13.
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

Rack B, Jückstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, Heinrigs M, Rammel G, Zwingers T, Sommer H, Friese K, Janni W.
Department of Gynecology and Obstetrics, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Ludwig-Maximilians-Universitaet, Muenchen, Germany. brigitte.rack@med.uni-muenchen.de


http://www.ncbi.nlm.nih.gov/corehtml...anres_full.gif
Abstract

BACKGROUND: There is strong evidence for the isolated tumour cells (ITCs) in the bone marrow of breast cancer patients having prognostic impact both at primary diagnosis and during recurrence-free follow-up. The goal of this study was to investigate the therapeutic efficacy of zoledronate on the persistence of ITC. PATIENTS AND METHODS: A total of 172 primary breast cancer patients without evidence of distant recurrence but detection of ITC in bone marrow were followed up. Zoledronate was administered every 4 weeks for 6 months to 31 patients who had completed surgery and adjuvant chemotherapy. In a matched-pair analysis, these patients were compared to 141 patients who did not receive additional zoledronate treatment. The bone marrow was re-examined after a median of 7.9 months (SD 0.89) and 11.5 months (SD 12.41; p=0.11), respectively. Patients were followed-up prospectively for a median of 39 months after the first aspiration. RESULTS: While ITCs were detected in all 172 patients at the time of first bone marrow aspiration, ITCs were detected in four patients (13%) following 6 months of zoledronate therapy in contrast to 38 patients (27%) of the control group (p=0.099). The reduction in cell numbers between the first and second aspiration reached statistical significance in the zoledronate group (p=0.02 vs. p=0.14). Persistent ITCs at the follow-up aspiration were associated with reduced recurrence-free survival (p=0.05). CONCLUSION: These results indicate a potential antineoplastic effect of the cell cycle-independent agent zoledronate on persisting ITCs in a dormant state.

PMID: 20592383 [PubMed - indexed for MEDLINE]

More on Zoledronic acid HERE

Re: Zoledronic acid (Zometa) and persistent/dormant cells
 

Thanks for posting this one, Rich66.

I feel my long post chemo treatment with frequent Zometa is a major reason I am NED. That and the almost 8 years of Herceptin.

Being hormone negative, my med onc wanted to give me everything else available in hopes of my present outcome.

It was expensive, but cancer is NOT nice, and requires a heavy hand in many of us.